These therapeutic benefits, along with its inhibitory effect on NF-κB target genes, and its commercial availability, significantly reduces the amount of time it would take to bring a drug to the market, which prompted us to study the effects of doxycycline in cells from patients with CTCL. Here, NFKB1 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.